<div id="readability-page-1"><div> <p>Health-care companies rose amid optimism about obesity-drug demand.</p> <p>   Shares of Novo Nordisk rose after the U.S. Food and Drug Administration approved the first GLP-1 weight-loss pill, a tablet formulation of the Danish company's drug branded as both Ozempic and Wegovy. The availability of pills for the medications that had already seen high demand in injection form is anticipated to bolster demand for the glucagon-like peptide inhibitors. </p> <p>   Shares of some other obesity-drug makers, including Viking Therapeutics, rose in sympathy. </p> <p>   A Baltimore city jury ordered Johnson &amp; Johnson to pay over $1.5 billion in a lawsuit that alleged the company's talc-based personal products gave a Maryland woman cancer. </p> <pre></pre> <p>   Write to Rob Curran at rob.curran@dowjones.com </p> <p>   (END) Dow Jones Newswires</p> <p>   December 23, 2025 18:13 ET (23:13 GMT)</p><p>Copyright (c) 2025 Dow Jones &amp; Company, Inc.</p></div></div>

VKTX

<p>Health-care stocks rose due to optimism about obesity-drug demand, with Novo Nordisk shares up after FDA approval of its GLP-1 weight-loss pill. This pill is expected to increase demand for glucagon-like peptide inhibitors. Shares of other obesity-drug makers, like Viking Therapeutics, also rose. Additionally, Johnson & Johnson was ordered to pay over $1.5 billion in a lawsuit alleging its talc-based products caused cancer.</p>

Health Care Up as Novo Nordisk Gains — Health Care Roundup